Baxter International (BAX) Projected to Release Earnings on Thursday

Baxter International (NYSE:BAX) is projected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Baxter International to post earnings of $0.36 per share and revenue of $2.7927 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $2.70 billion during the quarter, compared to analyst estimates of $2.62 billion. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company posted $0.62 EPS. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Baxter International Stock Down 2.0%

Shares of NYSE:BAX opened at $21.77 on Thursday. The company has a market capitalization of $11.25 billion, a price-to-earnings ratio of -10.22, a P/E/G ratio of 3.58 and a beta of 0.62. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.85 and a quick ratio of 1.23. The business’s 50-day moving average is $20.51 and its 200-day moving average is $19.41. Baxter International has a 1 year low of $15.73 and a 1 year high of $29.35.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Friday, May 29th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.88%.

Institutional Trading of Baxter International

Hedge funds have recently bought and sold shares of the business. State of Tennessee Department of Treasury grew its position in Baxter International by 99.1% in the 4th quarter. State of Tennessee Department of Treasury now owns 111,858 shares of the medical instruments supplier’s stock valued at $2,245,000 after purchasing an additional 55,674 shares during the period. Jump Financial LLC raised its holdings in Baxter International by 5.7% during the fourth quarter. Jump Financial LLC now owns 15,968 shares of the medical instruments supplier’s stock worth $305,000 after buying an additional 854 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Baxter International by 35.6% in the fourth quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock valued at $65,216,000 after buying an additional 894,761 shares in the last quarter. Captrust Financial Advisors grew its holdings in shares of Baxter International by 5.4% during the fourth quarter. Captrust Financial Advisors now owns 49,035 shares of the medical instruments supplier’s stock valued at $937,000 after buying an additional 2,496 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Baxter International during the fourth quarter valued at about $748,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BAX shares. Weiss Ratings upgraded Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. TD Cowen cut their price target on Baxter International from $22.00 to $20.00 in a report on Friday, May 1st. Zacks Research downgraded shares of Baxter International from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Barclays lifted their price objective on shares of Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Finally, Evercore dropped their target price on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $19.91.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.